Abira Medical Laboratories, LLC, d/b/a Genesis Diagnostics v. Anthem Health Plans of Virginia, Inc., d/b/a Anthem Blue Cross Blue Shield of Virginia, et al.

CourtDistrict Court, E.D. Virginia
DecidedFebruary 3, 2026
Docket3:25-cv-00108
StatusUnknown

This text of Abira Medical Laboratories, LLC, d/b/a Genesis Diagnostics v. Anthem Health Plans of Virginia, Inc., d/b/a Anthem Blue Cross Blue Shield of Virginia, et al. (Abira Medical Laboratories, LLC, d/b/a Genesis Diagnostics v. Anthem Health Plans of Virginia, Inc., d/b/a Anthem Blue Cross Blue Shield of Virginia, et al.) is published on Counsel Stack Legal Research, covering District Court, E.D. Virginia primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Abira Medical Laboratories, LLC, d/b/a Genesis Diagnostics v. Anthem Health Plans of Virginia, Inc., d/b/a Anthem Blue Cross Blue Shield of Virginia, et al., (E.D. Va. 2026).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF VIRGINIA Richmond Division

ABIRA MEDICAL LABORATORIES, ) LLC, d/b/a GENESIS DIAGNOSTICS, ) ) Plaintiff, ) ) v. ) Civil Action No. 3:25CV108 (RCY) ) ANTHEM HEALTH PLANS OF ) VIRGINIA, INC., ) d/b/a ANTHEM BLUE CROSS BLUE ) SHIELD OF VIRGINIA, et al., ) ) Defendants. ) )

MEMORANDUM OPINION

This is an ERISA and contract dispute action brought by Plaintiff Abira Medical Laboratories, LLC, d/b/a Genesis Diagnostics (“Genesis”) against Defendant Anthem Health Plans of Virginia, Inc., d/b/a Anthem Blue Cross Blue Shield of Virginia (“Anthem”). The matter is before the Court on Defendant’s Motion to Dismiss. The Motion has been fully briefed. The Court dispenses with oral argument because the facts and legal contentions are adequately presented in the materials before the Court, and oral argument would not aid in the decisional process. E.D. Va. Loc. Civ. R. 7(J). For the reasons stated below, the Court will deny the Motion to Dismiss with respect to Counts One through Three and Defendant’s request for severance. The Court will grant the Motion to Dismiss with respect to Count Four, without prejudice. I. RELEVANT PROCEDURAL HISTORY Plaintiff filed its Complaint on February 11, 2025. ECF No. 1. After timely service and two extensions, Anthem filed a Motion to Dismiss the Complaint on May 7, 2025. Mot. Dismiss, ECF No. 18. On May 28, 2025, following a consented-to extension, Plaintiff filed a Memorandum in Opposition to Anthem’s Motion to Dismiss. Resp. Opp’n, ECF No. 22. Anthem then filed a Reply on June 10, 2025. Reply, ECF No. 23. Finding no oral argument to be necessary, the Court proceeds to disposition of the Motion on the briefs. II. STANDARD OF REVIEW “A motion to dismiss under Rule 12(b)(6) tests the sufficiency of a complaint; importantly, it does not resolve contests surrounding the facts, the merits of a claim, or the applicability of defenses.” Megaro v. McCollum, 66 F.4th 151, 157 (4th Cir. 2023) (quoting Republican Party of N.C. v. Martin, 980 F.2d 943, 952 (4th Cir. 1992)). Federal Rule of Civil Procedure 8 only requires

that a complaint set forth “‘a short and plain statement of the claim showing that the pleader is entitled to relief,’ in order to ‘give the defendant fair notice of what the . . . claim is and the grounds upon which it rests.’” Bell Atl. Corp. v. Twombly, 550 U.S. 544, 555 (2007) (quoting Conley v. Gibson, 355 U.S. 41, 47 (1957)). While the complaint’s “[f]actual allegations must be enough to raise a right to relief above the speculative level,” “detailed factual allegations” are not required to satisfy the pleading requirement of Federal Rule 8(a)(2). Id. (citations omitted). The plaintiff’s well-pleaded allegations are assumed to be true, and the complaint is viewed in the light most favorable to the plaintiff. Mylan Labs., Inc. v. Matkari, 7 F.3d 1130, 1134 (4th Cir. 1993) (citations omitted); see also Martin, 980 F.2d at 952. Such a standard, however, does not require accepting any unreasonable inferences or a plaintiff’s legal conclusions. Philips v. Pitt Cnty. Mem’l Hosp.,

572 F.3d 176, 180 (4th Cir. 2009). “To survive a motion to dismiss, a complaint must contain sufficient factual matter, accepted as true, to ‘state a claim to relief that is plausible on its face.’” Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009) (quoting Twombly, 550 U.S. at 570). “A claim has facial plausibility when the plaintiff pleads factual content that allows the court to draw the reasonable inference that the defendant is liable for the misconduct alleged.” Id. (citing Twombly, 550 U.S. at 556). “The plausibility standard is not akin to a ‘probability requirement,’ but it asks for more than a sheer possibility that a defendant has acted unlawfully.” Id. “Labels and conclusions,” a “formulaic recitation of the elements,” and “naked assertions” without factual enhancement are insufficient. Id. In deciding whether a complaint will survive a motion to dismiss, a court evaluates the complaint in its entirety, as well as documents attached or incorporated into the complaint. E.I. du Pont de Nemours & Co. v. Kolon Indus., Inc., 637 F.3d 435, 448 (4th Cir. 2011) (citing Sec’y of State for Defence v. Trimble Navigation Ltd., 484 F.3d 700, 705 (4th Cir. 2007); Phillips v. LCI

Int’l Inc., 190 F.3d 609, 618 (4th Cir. 1999)). III. FACTUAL ALLEGATIONS Plaintiff is a medical testing business offering clinical laboratory, pharmacy, genetic, addiction rehabilitation, and COVID-19 testing services based on requisitions submitted by medical service providers on behalf of (as relevant here) Defendant’s subscribers/members (hereinafter “insureds”). Compl. ¶ 15, ECF No. 1. These service requisitions contained an assignment of benefits (“AOB”) provision and were executed by each insured for whom Plaintiff provided services. Id. ¶¶ 16–18. The AOB contained the following language: I hereby assign all rights and benefits under my health plan and direct payments be made to Genesis Diagnostics for laboratory services furnished to me by Genesis Diagnostics. I irrevocably designate authorize and appoint Genesis Diagnostics or its assigned affiliates as my true and lawful attorney-in-fact for the purpose of submitting my claims and pursuing any request, disclosure, appeal, litigation or other remedies in accordance with the benefits and rights under my health plan and in accordance with any federal or state laws. If my health plan fails to abide by my authorization and makes payment directly to me, I agree to endorse the insurance check and forward it to Genesis Diagnostics immediately upon receipt. I hereby authorize Genesis Diagnostics or its assigned affiliates to contact me for billing or payment purposes by phone, text message, or email with the contact information that I have provided to Genesis Diagnostics, in compliance with federal and state laws. Id. ¶ 17. Some of the insureds obtained their insurance policies through employee benefit plans regulated by the federal Employee Retirement Income Security Act (ERISA). Id. ¶¶ 25–27, 37 (describing ERISA-governed benefits claims and non-ERISA governed claims). Exhibit 1, attached to the Complaint, details Defendant’s insureds to whom Plaintiff provided testing services, as well as the dates of services, the amounts billed for those services, ascension numbers, and policy identification and claim numbers. Id. ¶ 18. There are over 2,000 claims in the Exhibit. Id. ¶ 50. Plaintiff alleges that Defendant, in response to claims submitted

under each insured’s plan, “blatantly disregarded . . . express obligations to pay Plaintiff for services rendered.” Id. ¶¶ 19, 31, 33. Defendant either wholly failed to respond to claims or employed a “contrived and meritless” rationale in rejecting them. Id. ¶¶ 20–22. Plaintiff alleges that it exhausted administrative remedies in pursuing payment. Id. ¶ 30. Defendant’s rejection and/or underpayment of Plaintiff’s claims resulted in compensatory, direct, or actual damages to Plaintiff in an amount not less than $2,898,730, in addition to all legal, equitable, consequential, and/or incidental damages to be determined by the trier of fact. Id. ¶¶ 22, 58. IV.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Crowell v. Shell Oil Co.
541 F.3d 295 (Fifth Circuit, 2008)
Conley v. Gibson
355 U.S. 41 (Supreme Court, 1957)
United Mine Workers of America v. Gibbs
383 U.S. 715 (Supreme Court, 1966)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Marks v. Watters
322 F.3d 316 (Fourth Circuit, 2003)
Elayne Wolf v. Federal National Mortgage
512 F. App'x 336 (Fourth Circuit, 2013)
Sikora and Associates v. Storey
311 F. App'x 568 (Fourth Circuit, 2008)
Philips v. Pitt County Memorial Hospital
572 F.3d 176 (Fourth Circuit, 2009)
Sales v. Kecoughtan Housing Co., Ltd.
690 S.E.2d 91 (Supreme Court of Virginia, 2010)
Ulloa v. Qsp, Inc.
624 S.E.2d 43 (Supreme Court of Virginia, 2006)
State Farm Mut. Auto. Ins. Co. v. Remley
618 S.E.2d 316 (Supreme Court of Virginia, 2005)
Pollard & Bagby, Inc. v. Pierce Arrow, L.L.C.
521 S.E.2d 761 (Supreme Court of Virginia, 1999)

Cite This Page — Counsel Stack

Bluebook (online)
Abira Medical Laboratories, LLC, d/b/a Genesis Diagnostics v. Anthem Health Plans of Virginia, Inc., d/b/a Anthem Blue Cross Blue Shield of Virginia, et al., Counsel Stack Legal Research, https://law.counselstack.com/opinion/abira-medical-laboratories-llc-dba-genesis-diagnostics-v-anthem-health-vaed-2026.